Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

Oral compared with injectable presentations of glucagon-like peptide-1 receptor agonism — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-007/5
Series
Evidence synthesis
Version
3.0
Published
16 Dec 2024
Last reviewed
16 Jul 2025
Next review
16 Jan 2027
Identifier
10.71829/cei.syn.7
Certainty
Moderate
Cycle
2024 Q4
Review type
Network meta-analysis
Search executed
25 Oct 2024

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
05 Sep 20240.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
29 Apr 20252.1Outcome addedAn additional outcome was added at the request of a public comment-period respondent. The addition is recorded here because it was made after protocol registration and is therefore post hoc.
24 Nov 20253.2Search re-runThe search was re-run to the current cycle date. Newly identified records were screened against the registered criteria without modification of those criteria.
Current version 3.0, ratified in the 2024 Q4 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
ACHIEVE-110 Aug 2024Redirected to a data-access portal
ACHIEVE-231 Jul 2024Supplied on request
ATTAIN-130 Aug 2024Refused
ATTAIN-211 Oct 2024Refused
SOUL23 Aug 2024Partially supplied
STRIDE08 Oct 2024Redirected to a data-access portal
FLOW27 Aug 2024Refused
STEP-HFpEF-DM08 Sep 2024Refused

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.